Seroba Life Sciences

News, insights, analysis and data

← Back to Seroba Life Sciences profile

Seroba Life Sciences related stories

All articles and analysis

  • Medical device startup PQ Bypass rakes in $60 mln
    Iris Dorbian- 14 January 2019

    Sunnyvale, California-based medical device startup PQ Bypass has raised $60 million in funding. Deerfield Management led the round with participation from other investors that included Seroba Life Sciences and MedTech Venture Partners.

  • Atlantic Therapeutics snags Series B funding
    Iris Dorbian- 7 January 2019

    Atlantic Therapeutics, a medical technology company focused on treating bladder leaks, has secured 28 million euros in Series B funding. LSP led the round with participation from other investors that included Andera Partners, Atlantic Bridge Ventures, Seroba Life Sciences and Earlybird Venture Capital.

  • Endotronix inks $45 mln Series D
    Iris Dorbian- 14 September 2018

    Lisle, Illinois-based Endotronix Inc, a digital health focused on advancing the treatment of heart failure, has raised $45 million in Series D funding. LSP led the round with participation from other investors that included Aperture Venture Partners, BioVentures Investors, Lumira Ventures, OSF Ventures, Seroba Life Sciences, SV Health Investors and Wanxiang Healthcare Investments.

  • Lundbeck to acquire VC-backed Prexton
    iris dorbian- 16 March 2018

    Lundbeck has agreed to acquire Prexton Therapeutics for 100 million euros and will later pay up to 805 million euros in development and sales milestones. Based in The Netherlands and in Switzerland, Prexton is a biopharmaceutical company. Prexton's investors include Forbion, Seroba Life Sciences, Sunstone Capital and Ysios Capital.

  • Canadian VC hits 16-year high in 2017 as top deals raise $1 bln
    Kirk Falconer- 8 January 2018

    For Canada’s venture capital market, 2017 was a remarkable year. The story is told partly in milestones. They include the largest financing of a local IT company in 25 years (Lightspeed); the largest round on record for an artificial-intelligence startup (Element AI), and strategic funding of a top maker of laser sensors used in self-driving cars (LeddarTech). They were among Canada’s top 10 venture-capital financings last year, which together raised more than $1 billion from investors. The number is based on PE Hub Canada’s list of the largest deals announced in 2017, supplemented by preliminary data from Thomson Reuters.

  • VC-backed MedLumics taps Greene as CEO and adds one to board
    Iris Dorbian- 28 November 2017

    Madrid-based MedLumics, a medical device company, has named James Greene as CEO and Giovanni Leo to its board of directors. Previously, Greene worked at Seroba Lifesciences, a Dublin-based venture firm where he was a partner while Leo was vice president of research and development for St. Jude Medical. MedLumics' backers include Edmond de Rothschild Investment Partners, Seroba Lifesciences, Innogest, Ysios and Caixa.

  • Fusion Pharmaceuticals lands $21 mln
    Iris Dorbian- 25 September 2017

    Hamilton, Ontario-based Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company, has raised an additional $21 million in Series A funding, bringing the total tally to $46 million. The investors in this round included Adams Street Partners, Seroba Life Sciences and Varian Medical Systems Inc.

  • Fusion Pharmaceuticals tops up Series A round, raises $57 mln
    Kirk Falconer- 25 September 2017

    Fusion Pharmaceuticals Inc has secured about $26 million (US$21 million) in the second close of its Series A financing. The additional funding, which brings the round to nearly $57 million (US$46 million) in total, was supplied by Adams Street Partners, Seroba Life Sciences and Varian Medical Systems Inc, among others. They join the backers of the round's first close, announced in February /canada/2017/2/3437306/ Hamilton, Ontario's Fusion, a spin-out of the Centre for Probe Development and Commercialization, is developing targeted radiotherapeutics for treating cancer. It will use the additional funds raised to develop its lead program, expand its pipeline, and form new strategic partnerships.

  • MedLumics pulls in Series B funds
    Iris Dorbian- 20 March 2017

    Madrid-based MedLumics, a cardiac device company focused on optically guided minimally invasive instruments, has secured 34.4 million euros in Series B financing. Edmond de Rothschild Investment Partners led the round with participation from other investors that included Seroba Life Sciences, Innogest Capital, Ysios Capital Partners and Caixa Capital Risc. In addition to the funding, EdRIP’s Olivier Litzka, Innogest’s Claudio Rumazza and Seroba’s James Green have been named to MedLumics' board of directors.